WAYNE, Pa., April 1 /PRNewswire-FirstCall/ -- Encorium Group, Inc. , a full service clinical research organization (CRO) conducting studies in over 30 countries for many of the world’s leading pharmaceutical and biotechnology companies, announced today that it will file a Form 12b-25 with the Securities and Exchange Commission, which will provide the Company with a 15- calendar day extension for filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2009. The Company’s independent registered accounting firm has not completed its audit of the Company’s financial statements and has not provided its report and consent for the Company’s Annual Report. The Company will file its Form 10-K as soon as its independent registered accounting firm provides its report on those financial statements and its consent.
About Encorium Group, Inc.
Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company’s mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women’s health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.
Encorium Group, Inc.
